The parental origin of new mutations in neurofibromatosis 2

被引:21
作者
Kluwe, L
Mautner, V
Parry, DM
Jacoby, LB
Baser, M
Gusella, J
Davis, K
Stavrou, D
MacCollin, M
机构
[1] Univ Hamburg, Hosp Eppendorf, Dept Neurosurg, Lab Brain Tumor Biol, D-20246 Hamburg, Germany
[2] Gen Hosp Ochsnezoll, Dept Neurol, Hamburg, Germany
[3] NCI, Genet Epidemiol Branch, Bethesda, MD 20892 USA
[4] Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA USA
[5] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[6] Univ Hamburg, Hosp Eppendorf, Dept Neuropathol, D-20246 Hamburg, Germany
关键词
parental origin; neurofibromatosis; 2; allele loss; mosaicism;
D O I
10.1007/s100480000088
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Neurofibromatosis 2 (NF2) is an autosomal dominant disorder characterized by schwannomas and meningiomas that develop after inactivation of both copies of the NF2 gene. Approximately half of all patients with NF2 have unaffected parents and the disease results from new mutations at the NF2 locus. Loss of heterozygosity (LOH) in tumor specimens due to deletions covering the normal NF2 allele can be used to infer the haplotypes surrounding underlying mutations and determine the allelic origin of new mutations. We studied 71 sporadic NF2 patients using both LOH and pedigree analysis and compared the parental origin of the new mutation with the underlying molecular change. In the 45 informative individuals, 31 mutations (69%) mere of paternal and 14 (31%) were of maternal origin (P=0.016). Comparison with corresponding constitutional mutations revealed no correlation between parental origin and the type or location of the mutations. However, in 4 of 6 patients with somatic mosaicism the NF2 mutation was of maternal origin. A slight parent of origin effect on severity of disease was found. Further clinical and molecular studies are needed to determine the basis of these unexpected observations.
引用
收藏
页码:17 / 24
页数:8
相关论文
共 51 条
[1]  
Ainsworth PJ, 1997, HUM MUTAT, V9, P452, DOI 10.1002/(SICI)1098-1004(1997)9:5<452::AID-HUMU12>3.3.CO
[2]  
2-V
[3]   ANALYSIS OF MUTATIONS IN THE SCH GENE IN SCHWANNOMAS [J].
BIJLSMA, EK ;
MEREL, P ;
BOSCH, DA ;
WESTERVELD, A ;
DELATTRE, O ;
THOMAS, G ;
HULSEBOS, TJM .
GENES CHROMOSOMES & CANCER, 1994, 11 (01) :7-14
[4]  
BOURN D, 1995, HUM GENET, V95, P712
[5]  
CARLSON KM, 1994, AM J HUM GENET, V55, P1076
[6]   PARENTAL ORIGIN OF MUTATIONS OF THE RETINOBLASTOMA GENE [J].
DRYJA, TP ;
MUKAI, S ;
PETERSEN, R ;
RAPAPORT, JM ;
WALTON, D ;
YANDELL, DW .
NATURE, 1989, 339 (6225) :556-558
[7]  
DURHAM I, 1999, NATURE, V402, P489
[8]  
Evans DA, 1998, KLUW S INF, V2, P63
[9]   A GENETIC-STUDY OF TYPE-2 NEUROFIBROMATOSIS IN THE UNITED-KINGDOM .1. PREVALENCE, MUTATION-RATE, FITNESS, AND CONFIRMATION OF MATERNAL TRANSMISSION EFFECT ON SEVERITY [J].
EVANS, DGR ;
HUSON, SM ;
DONNAI, D ;
NEARY, W ;
BLAIR, V ;
TEARE, D ;
NEWTON, V ;
STRACHAN, T ;
RAMSDEN, R ;
HARRIS, R .
JOURNAL OF MEDICAL GENETICS, 1992, 29 (12) :841-846
[10]   Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations [J].
Evans, DGR ;
Trueman, L ;
Wallace, A ;
Collins, S ;
Strachan, T .
JOURNAL OF MEDICAL GENETICS, 1998, 35 (06) :450-455